Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial

The Lancet Oncology

Volumn 17, Issue 4, 2016, Pages 496-508

  Garcia Manero, Guillermo ^a   Fenaux, Pierre ^b   Al Kali, Aref ^c   Baer, Maria R ^d   Sekeres, Mikkael A ^e   Roboz, Gail J ^f   Gaidano, Gianluca ^g   Scott, Bart L ^h   Greenberg, Peter ⁱ   Platzbecker, Uwe ^j   Steensma, David P ^k   Kambhampati, Suman ^l   Kreuzer, Karl Anton ^m   Godley, Lucy A ⁿ   Atallah, Ehab ^o   Collins, Robert ^p   Kantarjian, Hagop ^a   Jabbour, Elias ^a   Wilhelm, Francois E ^q   Azarnia, Nozar ^q   Silverman, Lewis R ^r   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^h USA   (United States)

ⁱ STANFORD CANCER INSTITUTE   (United States)

^j UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^k DANA FARBER CANCER INSTITUTE   (United States)

^l UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^m UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

ⁿ UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^o MEDICAL COLLEGE OF WISCONSIN   (United States)

^p UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^q Onconova Therapeutics Inc   (United States)

^r MOUNT SINAI SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; CYTARABINE; DECITABINE; RIGOSERTIB; GLYCINE; SULFONE;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BELGIUM; BLOOD TRANSFUSION REACTION; BRAIN HEMORRHAGE; CARDIOPULMONARY INSUFFICIENCY; CATHETER INFECTION; CELLULITIS; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; COUGHING; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TREATMENT FAILURE; DYSPNEA; EPISTAXIS; EUROPE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; FRANCE; FUNGEMIA; GASTROINTESTINAL HEMORRHAGE; GERMANY; HEADACHE; HEART ARREST; HEART INFARCTION; HEMATURIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; HYPOXIA; INSOMNIA; ITALY; KIDNEY INJURY; KIDNEY METASTASIS; LEUKOCYTOSIS; LEUKOPENIA; LOW DRUG DOSE; LUNG DISEASE; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MEGACOLON; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; MUSCLE WEAKNESS; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; ORAL BLEEDING; OVERALL SURVIVAL; PANCYTOPENIA; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PNEUMATOSIS INTESTINALIS; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; SEPSIS; SEPTIC SHOCK; SPAIN; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS INFECTION; SUBARACHNOID HEMORRHAGE; THROMBOCYTOPENIA; UNITED STATES; UNIVERSITY HOSPITAL; URINARY TRACT INFECTION; VOMITING; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DNA METHYLATION; DRUG ADMINISTRATION; DRUG EFFECTS; KAPLAN MEIER METHOD; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PATHOLOGY; RISK; TREATMENT OUTCOME;

AGED; AZACITIDINE; DISEASE-FREE SURVIVAL; DNA METHYLATION; DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; GLYCINE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RISK; SULFONES; TREATMENT OUTCOME;

EID: 84959931622     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)00009-7     Document Type: Article

References (33)

1. 1 National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Myelodysplastic Syndromes. Version 1. 2016.
2. 2 Ma, X, Does, M, Raza, A, Mayne, ST, Myelodysplastic syndromes: incidence and survival in the United States. Cancer 109 (2007), 1536–1542.
3. 3 Sekeres, MA, Schoonen, WM, Kantarjian, H, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst 100 (2008), 1542–1551.
4. 4 Rudrapatna, VK, Morley, K, Boucher, KM, et al. Phase I trial of low-dose oral clofarabine in myelodysplastic syndromes patients who have failed frontline therapy. Leuk Res 39 (2015), 835–839.
5. 5 Greenberg, P, Cox, C, LeBeau, MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 (1997), 2079–2088.
6. 6 Greenberg, PL, Tuechler, H, Schanz, J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120 (2012), 2454–2465.
7. 7 Jabbour, E, Garcia-Manero, G, Batty, N, et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer 116 (2010), 3830–3834.
8. 8 Bello, C, Yu, D, Komrokji, RS, et al. Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. Cancer 117 (2011), 1463–1469.
9. 9 Jabbour, E, Garcia-Manero, G, Shan, J, et al. Outcome of patients (pts) with myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) post decitabine failure. Blood, 112, 2008, 1659.
10. 10 Prebet, T, Gore, SD, Esterni, B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 29 (2011), 3322–3327.
11. 11 Garcia-Manero, G, Fenaux, P, Hypomethylating agents and other novel strategies in myelodysplastic syndromes. J Clin Oncol 29 (2011), 516–523.
12. 12 Fenaux, P, Mufti, GJ, Hellstrom-Lindberg, E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10 (2009), 223–232.
13. 13 Silverman, LR, Fenaux, P, Mufti, GJ, et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer 117 (2011), 2697–2702.
14. 14 Reddy, EP, Divakar, SK, Vasquez-Del Carpio, R, et al. Rigosertib blocks RAS signaling by acting as a small molecule RAS mimetic that binds to the RAS-binding domains of RAS effector proteins. Blood, 124, 2014, 5616.
15. 15 Chun, AW, Cosenza, SC, Taft, DR, Maniar, M, Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent. Cancer Chemother Pharmacol 65 (2009), 177–186.
16. 16 Reddy, MV, Venkatapuram, P, Mallireddigari, MR, et al. Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2',4',6'-trimethoxystyrylsulfonyl) methyl]phenylamino}acetate (ON 01910.Na): synthesis, structure-activity relationship, and biological activity. J Med Chem 54 (2011), 6254–6276.
17. 17 Divakar, S, Vasqez-Del Caprio, R, Baker, SJ, et al. Targeting the Ras-binding domain of RAS effector proteins by a small molecule inhibitor, rigosertib. Cancer Res, 74(19 suppl), 2014, LB108.
18. 18 Park, IW, Reddy, MVR, Reddy, EP, Groopman, JE, Evaluation of novel cell cycle inhibitors in mantle cell lymphoma. Oncogene 26 (2007), 5635–5642.
19. 19 Prasad, A, Park, IW, Allen, H, et al. Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells. Oncogene 28 (2009), 1518–1528.
20. 20 Sloand, EM, Pfannes, L, Reddy, R, Reddy, P, Groopman, JS, Young, NS, Suppression of cyclin D1 by 01910.Na is associated with decreased survival of trisomy 8 myelodysplastic bone marrow progenitors: a potential targeted therapy. Blood, 110, 2007, 822.
21. 21 Sloand, EM, Pfannes, L, Chen, G, et al. CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins. Blood 109 (2007), 2399–2405.
22. 22 Olnes, MJ, Shenoy, A, Weinstein, B, et al. Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na. Leuk Res 36 (2012), 982–989.
23. 23 Silverman, LR, Greenberg, P, Raza, A, et al. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy. Hematol Oncol 33 (2015), 57–66.
24. 24 Seetharam, M, Fan, AC, Tran, M, et al. Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. Leuk Res 36 (2012), 98–103.
25. 25 Brunning, RD, Orazi, A, Porwit, A, et al. Myelodysplastic syndromes/neoplasms, overview, 4th edn., 2008, IARC Press, 88–93.
26. 26 Bennett, JM, Catovsky, D, Daniel, MT, et al., for the French-American-British (FAB) co-operative group. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51 (1982), 189–199.
27. 27 Cheson, BD, Greenberg, PL, Bennett, JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108 (2006), 419–425.
28. 28 Shaffer, L, Tommerup, N, (eds.) ISCN 2005: an international system for human cytogenetic nomenclature, 2005, S Karger AG, Basel.
29. 29 Haase, D, Germing, U, Schanz, J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110 (2007), 4385–4395.
30. 30 Jaiswal, S, Fontanillas, P, Flannick, J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371 (2014), 2488–2498.
31. 31 Genovese, G, Kahler, A, Handsaker, RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 371 (2014), 2477–2487.
32. 32 Bejar, R, Clinical and genetic predictors of prognosis in myelodysplastic syndromes. Haematologica 99 (2014), 956–964.
33. 33 Naqvi, K, Jabbour, E, Bueso-Ramos, C, et al. Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood 118 (2011), 4690–4693.